Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$2.94 -14.5%	$2.14	$1.42 ▼ $5.97	$48.06M	1.33	139,693 shs	105,851 shs
DMAC DiaMedica Therapeutics	$4.12 -2.4%	$4.05	$3.19 ▼ $6.82	$180.97M	1.25	392,943 shs	203,997 shs
RAPT Rapt Therapeutics	$10.49 -2.9%	$9.23	$5.67 ▼ $26.56	$178.59M	0.01	98,493 shs	31,794 shs
SXTC China SXT Pharmaceuticals	$1.70 +9.0%	$1.70	$0.95 ▼ $8.72	$181M	1.24	67,715 shs	88,794 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	-14.53%	-22.63%	+86.08%	+68.00%	-37.04%
DMAC DiaMedica Therapeutics	-2.37%	-18.42%	+15.41%	-2.60%	+25.61%
RAPT Rapt Therapeutics	-2.87%	-21.19%	+30.96%	+35.63%	-58.24%
SXTC China SXT Pharmaceuticals	+8.97%	+6.92%	-4.49%	-25.44%	-80.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALC CalciMedica	2.9752 of 5 stars	3.5	5.0	0.0	1.1	3.3	0.0
DMAC DiaMedica Therapeutics	1.8178 of 5 stars	3.5	0.0	0.0	3.6	1.7	0.0
RAPT Rapt Therapeutics	4.0195 of 5 stars	3.3	1.0	4.2	3.1	1.7	1.3
SXTC China SXT Pharmaceuticals	0.4957 of 5 stars	0.0	5.0	0.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALC CalciMedica	3.00	Buy	$16.00	444.22% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$10.75	160.92% Upside
RAPT Rapt Therapeutics	2.57	Moderate Buy	$20.57	96.11% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CALC, RAPT, SXTC, and DMAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	RAPT Rapt Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$14.00
7/22/2025	RAPT Rapt Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$31.00
7/18/2025	DMAC DiaMedica Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $14.00
7/18/2025	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $11.00
7/18/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
5/29/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
5/22/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$48.00
5/15/2025	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALC CalciMedica	N/A	N/A	N/A	N/A	$1.07 per share	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
RAPT Rapt Therapeutics	$1.53M	113.40	N/A	N/A	$11.51 per share	0.91
SXTC China SXT Pharmaceuticals	$1.93M	102.20	N/A	N/A	$243.66 per share	0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALC CalciMedica	-$13.70M	-$1.56	N/A	N/A	N/A	N/A	-171.81%	-100.43%	8/11/2025 (Estimated)
DMAC DiaMedica Therapeutics	-$24.44M	-$0.64	N/A	N/A	N/A	N/A	-61.35%	-55.53%	8/6/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$19.20	N/A	N/A	N/A	N/A	-81.47%	-70.24%	8/6/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest CALC, RAPT, SXTC, and DMAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.68	N/A	N/A	N/A	N/A	N/A
8/11/2025	N/A	CALC CalciMedica	-$0.44	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	DMAC DiaMedica Therapeutics	-$0.18	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	CALC CalciMedica	-$0.43	-$0.36	+$0.07	-$0.36	N/A	N/A
5/13/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A
5/8/2025	Q1 2025	RAPT Rapt Therapeutics	-$2.48	-$0.64	+$1.84	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALC CalciMedica	0.79	5.66	5.66
DMAC DiaMedica Therapeutics	N/A	8.02	8.02
RAPT Rapt Therapeutics	N/A	21.11	21.11
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALC CalciMedica	N/A
DMAC DiaMedica Therapeutics	10.12%
RAPT Rapt Therapeutics	99.09%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
CALC CalciMedica	41.55%
DMAC DiaMedica Therapeutics	7.30%
RAPT Rapt Therapeutics	2.36%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
DMAC DiaMedica Therapeutics	20	42.88 million	39.75 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable

CALC, RAPT, SXTC, and DMAC Headlines

Recent News About These Companies

China SXT Pharmaceuticals Inc. (SXTC) Stock Price Today - WSJ

July 30 at 8:37 AM | wsj.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Trading Down 1.3% - What's Next?

July 30 at 2:14 AM | marketbeat.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Price Down 10.1% - Here's Why

July 8, 2025 | marketbeat.com

China SXT Pharmaceuticals, Inc. (SXTC) - Yahoo Finance

July 4, 2025 | sg.finance.yahoo.com

China SXT Pharmaceuticals Inc News (SXTC) - Investing.com

June 25, 2025 | investing.com

China SXT Pharmaceuticals Issues 90 Million Shares Following Warrant Exercise

June 16, 2025 | tipranks.com

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.comM

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.comB

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

china sxt pharmaceuticals - SXTC

October 3, 2024 | foxbusiness.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC, RAPT, SXTC, and DMAC Company Descriptions

CalciMedica NASDAQ:CALC

$2.94 -0.50 (-14.53%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.94 +0.00 (+0.17%)

As of 08/1/2025 06:35 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

DiaMedica Therapeutics NASDAQ:DMAC

$4.12 -0.10 (-2.37%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.10 -0.02 (-0.49%)

As of 08/1/2025 07:29 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Rapt Therapeutics NASDAQ:RAPT

$10.49 -0.31 (-2.87%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.52 +0.03 (+0.24%)

As of 08/1/2025 07:04 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

China SXT Pharmaceuticals NASDAQ:SXTC

$1.70 +0.14 (+8.97%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$1.68 -0.02 (-1.47%)

As of 08/1/2025 07:48 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time